Company intelligence / Profile preview

Votis Subdermal Imaging Technologies

Jerusalem, Jerusalem District/Jerusalem Area, Israelprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company’s lead device, PedCheck™, began a pilot feasibility study at Hadassah Medical Center in Jerusalem in May 2022 to assess its usability and safety for screening peripheral artery disease. The device has not yet been approved or cleared for sale. No published clinical results as of June 2025.

Therapeutic areas: CardiovascularEndocrinology
Modalities: DeviceNon-pharmacological therapy
Industry: Medical Imaging

Partnerships

Columbia University (exclusive worldwide license for core imaging technology)

Beyond the preview

Go deeper on Votis Subdermal Imaging Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Votis Subdermal Imaging Technologies.

Explore the full profile